IssuerAnnouncementDetailsV2Portlet

Actions

Dr. Soliman Abdel Kader Fakeeh Hospital Co. Announces Contract Sign Off with Arabtec Jardaneh & Partners Engineering Consulting Company for the new Hospital Dr. Soliman Fakeeh MASAR in Makkah

4017
FAKEEH CARE
2.80 %
1446/11/14     12/05/2025 08:00:30

Element ListExplanation
Introduction Dr. Soliman Abdulkader Fakeeh Hospital Company ("DSFH") and its subsidiaries ("Fakeeh Care Group", "Group", "Fakeeh Care") is pleased to announce that it’s subsidiary company Dr. Soliman Fakeeh Medical Hospital Company Masar ("DSFH-Masar") has signed a supervision services contract with Arabtec Jardaneh & Partners Engineering Consulting Company to supervise and oversee the construction of the new Dr. Soliman Fakeeh Hospital MASAR in Makkah.
Date of Announcement of the Award 2025-05-11 Corresponding to 1446-11-13
Contract Subject Matter Provision of full construction‑site supervision and consultancy services for the Dr. Soliman Fakeeh Hospital MASAR in Makkah, including monitoring schedule, quality, safety, and cost compliance.
The Entity with Which the Contract was Signed Arabtec Jardaneh & Partners Engineering Consulting Company
Date of Signing the Contract 2025-05-11 Corresponding to 1446-11-13
Contract Value SAR 17,189,100 (exclusive of VAT)
Contract Details End‑to‑end supervision of civil, structural, MEP and architectural works; shop‑drawing & submittal approvals; progress reporting; testing & commissioning oversight; and final handover documentation.
Contract Duration 42 months beginning on the contract‑signing date (extendable if the main construction contract is extended).
Financial Impact and the Relevant Period It is expected that the contract will affect the Group's financial results over the contract duration.
Related Parties NA
Additional Information NA

The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.

Company Performance

Add To Watchlist
In your Watchlist
Add To Watchlist
Key Parameters
Last Price
Net Change  (%)
Value Traded (Sar)
Volume Traded
See The Company Profile

LoginPortletPopupv2

Actions

AddtoWatchlistv2

Actions
NO PORTLET SESSION YET